…
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People's Republic of China.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Ascletis Pharma Inc is a China-based biopharmaceutical company developing and commercializing therapeutic candidates, primarily in liver disease and oncology, and is quoted on the U.S. OTC Pink market. Long-term growth drivers may include clinical pipeline progress, regulatory approvals, and strategic partnerships that could support commercialization and geographic expansion. Investors may find exposure to specialty therapies in underserved indications attractive.
Key investment risks are significant clinical and regulatory uncertainty, intense competition from larger pharmaceutical companies, funding and liquidity constraints tied to its Pink listing, and limited public disclosures that reduce transparency.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -350.10M | -300.94M | -144.72M | -314.84M | -199.02M |
| Net income | -350.59M | -300.94M | -144.72M | -314.84M | -199.02M |
| Selling general administrative | - | 101.74M | 62.58M | 15.43M | 16.49M |
| Selling and marketing expenses | - | - | 0.39M | 16.98M | 20.87M |
| Gross profit | -16.65M | 0.73M | 25.99M | -24.69M | 39.17M |
| Reconciled depreciation | - | 20.45M | 18.48M | 30.19M | 29.55M |
| Ebit | -471.27M | -404.63M | -144.57M | -262.82M | -195.90M |
| Ebitda | -454.11M | -390.45M | -126.09M | -232.63M | -166.35M |
| Depreciation and amortization | 17.16M | 14.18M | 18.48M | 30.19M | 29.55M |
| Operating income | -471.27M | -295.42M | -300.21M | -262.82M | -195.90M |
| Other operating expenses | 473.25M | 296.70M | 356.80M | 393.72M | 260.96M |
| Interest expense | 0.16M | 0.24M | 0.14M | 0.16M | 0.12M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | - | 92.24M | 99.28M | 44.16M | 22.51M |
| Net interest income | - | 91.99M | 99.13M | 44.01M | 22.38M |
| Income tax expense | -0.49M | - | 95.40M | - | - |
| Total revenue | 1.98M | 1.28M | 56.60M | 54.09M | 76.88M |
| Total operating expenses | 454.63M | 296.15M | 326.20M | 314.94M | 223.26M |
| Cost of revenue | 18.62M | 0.55M | 30.61M | 78.78M | 37.70M |
| Total other income expense net | 121.17M | -5.52M | 155.49M | -52.03M | -3.12M |
| Net income from continuing ops | - | -300.94M | -144.72M | -314.84M | -199.02M |
| Net income applicable to common shares | - | - | - | -314.84M | -199.02M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2067.57M | 2124.57M | 2491.01M | 2657.04M | 2829.96M |
| Intangible assets | - | 12.12M | 26.32M | 16.56M | 78.21M |
| Other current assets | 4.75M | 13.74M | 19.43M | 8.12M | 2.34M |
| Total liab | 129.94M | 158.41M | 148.94M | 117.16M | 100.89M |
| Total stockholder equity | 1935.24M | 1966.16M | 2342.07M | 2539.89M | 2729.07M |
| Deferred long term liab | - | - | - | 0.70M | 0.42M |
| Other current liab | 123.44M | 142.70M | 132.60M | 102.64M | 88.35M |
| Common stock | 0.68M | 0.69M | 0.73M | 0.74M | 0.75M |
| Capital stock | - | 0.69M | 0.73M | 0.74M | 0.75M |
| Retained earnings | - | -1475.34M | -1174.40M | -1029.69M | -714.85M |
| Other liab | - | - | - | 7.15M | 8.73M |
| Other assets | - | - | - | 1.91M | 0.83M |
| Cash | 1444.24M | 865.73M | 330.12M | 2470.83M | 2495.50M |
| Total current liabilities | 127.66M | 153.05M | 140.68M | 108.19M | 90.97M |
| Current deferred revenue | - | - | -5.71M | - | - |
| Net debt | -1439.08M | -858.10M | -321.70M | -2466.60M | -2492.75M |
| Short term debt | 2.87M | 6.25M | 5.71M | 2.42M | 1.57M |
| Short long term debt total | 5.16M | 7.63M | 8.42M | 4.24M | 2.75M |
| Other stockholder equity | 1934.56M | 2693.26M | 2791.18M | 3568.83M | 2728.33M |
| Property plant equipment | - | - | - | 71.83M | 77.51M |
| Total current assets | 1921.69M | 1970.78M | 2332.76M | 2544.73M | 2631.55M |
| Net tangible assets | - | - | - | 2523.33M | 2650.86M |
| Short term investments | 457.59M | 1081.80M | 1969.29M | 11.20M | 5.20M |
| Net receivables | 13.23M | 5.14M | 4.00M | 23.87M | 67.39M |
| Inventory | 1.87M | 4.37M | 6.07M | 20.52M | 56.23M |
| Accounts payable | 1.34M | 0.03M | 0.65M | 3.13M | 1.05M |
| Accumulated other comprehensive income | - | 747.55M | 724.56M | - | - |
| Non currrent assets other | 0.46M | 1081.88M | 1969.92M | 11.90M | 5.62M |
| Non current assets total | 145.88M | 153.79M | 158.25M | 112.32M | 198.41M |
| Capital lease obligations | - | 7.63M | 8.42M | 4.24M | 2.75M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | 978.91M | 149.84M | -1297.39M | -269.78M | 170.96M |
| Change to liabilities | - | - | 0.49M | -2.48M | -7.44M |
| Total cashflows from investing activities | 978.91M | 149.84M | -1297.39M | -274.49M | 132.30M |
| Net borrowings | - | - | -2.22M | -2.28M | -1.93M |
| Total cash from financing activities | -103.51M | -81.50M | -1.42M | -31.10M | -21.67M |
| Change to operating activities | - | - | 16.41M | 24.37M | -6.67M |
| Net income | -300.94M | -144.72M | -314.84M | -199.02M | -209.24M |
| Change in cash | 534.21M | -73.65M | -1323.64M | -483.09M | -84.54M |
| Begin period cash flow | 330.12M | 403.77M | 1727.41M | 2210.50M | 2295.04M |
| End period cash flow | 864.33M | 330.12M | 403.77M | 1727.41M | 2210.50M |
| Total cash from operating activities | -341.58M | -144.16M | -142.45M | -146.93M | -84.91M |
| Issuance of capital stock | - | 0.00M | 0.96M | - | - |
| Depreciation | 20.45M | 18.48M | 30.19M | 29.55M | 27.16M |
| Other cashflows from investing activities | 121.09M | -12.82M | 3.32M | 2.48M | 0.29M |
| Change to inventory | -3.60M | -8.05M | -12.84M | -5.07M | -18.37M |
| Change to account receivables | 5.28M | 18.44M | 29.74M | -26.99M | 42.98M |
| Sale purchase of stock | -98.53M | -78.96M | 0.00M | -28.69M | -19.60M |
| Other cashflows from financing activities | -0.24M | -0.14M | -2.38M | -2.41M | -2.07M |
| Change to netincome | - | - | 108.08M | 32.29M | 86.22M |
| Capital expenditures | 2.15M | 19.16M | 14.40M | 7.20M | 38.96M |
| Change in working capital | 13.79M | 38.53M | 33.81M | -10.18M | 10.43M |
| Stock based compensation | 3.00M | 1.33M | 3.19M | 7.13M | 4.61M |
| Other non cash items | -77.89M | -57.78M | 105.20M | 25.59M | 82.13M |
| Free cash flow | -343.73M | -163.32M | -156.85M | -154.13M | -123.87M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ASCLF Ascletis Pharma Inc |
- -% |
0.56 | - | - | 1195.58 | 7.81 | 7500.86 | -0.13 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People's Republic of China.
| Name | Title | Year Born |
|---|---|---|
| Dr. Jinzi Jason Wu | Founder, Chairman & CEO | 1963 |
| Dr. Handan He Ph.D. | Chief Scientific Officer | 1962 |
| Ms. Hejingdao Wu | Sr. VP of Operations & Exec. Director | 1974 |
| Ms. Yuemei Yan | Sr. VP of Clinical Devel. Operations | 1970 |
| Dr. Kristjan Sigurdur Gudmundsson | Sr. Consultant & Head of Discovery | 1968 |
| Dr. George Zhengzhi Hill | Sr. Consultant & Chief Medical Advisor | 1951 |
| Mr. John P. Gargiulo M.B.A. | Chief Bus. Officer | NA |
| Mr. Ming Fai Chung CPA | Company Sec. | NA |
| Dr. Jinzi Jason Wu Ph.D. | Founder, Chairman & CEO | 1964 |
| Ms. Hejingdao Wu | Senior VP of Operations & Executive Director | 1974 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.